Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

t. After median follow up of 13.6 months, median progression-free survival and overall survival have not been reached. Side effects were manageable and included hematologic toxicity and peripheral neuropathy.

Safety and Efficacy of Lenalidomide, VELCADE and dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: A Phase I/II Study (Abstract #8520)

This Phase I/II study of VcRD combination therapy was designed to determine the maximum tolerated dose (MTD) and efficacy in previously untreated MM patients. The preliminary analysis included 66 evaluable patients, who received VELCADE at 1.0 mg/m2 or 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21-day schedule. Patients also received lenalidomide at 15, 20 or 25 mg on days 1 through 14 and dexamethasone at 40 or 20 mg on the day of and day after each VELCADE dose. Patients were treated for up to eight cycles at four planned dose levels. Maximum planned dose was VELCADE 1.3 mg/m2, lenalidomide 25 mg and dexamethasone 20 mg. Response was assessed by modified EBMT criteria and International Myeloma Working Group criteria. Results were presented by Paul Richardson, M.D., Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston and showed a CR rate of 35 percent at maximum planned dose and a 100 percent overall response rate (CR + partial response). Side effects were manageable and included lymphopenia, thrombocytopenia, hypophosphatemia and neutropenia. No grade 4 peripheral neuropathy was observed.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
(Date:7/2/2015)... , June 25, 2015 ... has announced the addition of the ... Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in Clinical Chemistry and ... is a new seven-country strategic analysis of ...
(Date:7/2/2015)... SHENZHEN, China , 2 de julio de 2015 ... secuenciación de ADN de alto rendimiento en ... por el American College of Pathologists (CAP). La instalación de ... el primer laboratorio de secuenciación de próxima generación que ... , cubriendo el más alto estándar en prácticas de ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2
... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is the new Medical ... largest network of independent freestanding emergency rooms in the United States. , “We are ... Plantation facility,” said Executive Medical Director of First Choice Emergency Room, Dr. James M. ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is ... dresses similar to those of celebrities will have the opportunity to get 10% discount ... This ensures that people do not have to use coupon codes or remember redemption ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ... her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June ... (D-R.I.), this Act seeks to decrease drug overdose – especially of heroin and ...
(Date:7/2/2015)... ... 2015 , ... “ LIFX ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... bulbs on the market. , According to the U.S. Department of Energy, it’s very ...
(Date:7/2/2015)... Washington, D.C. (PRWEB) , ... July 02, 2015 , ... ... kicking off the 2015 swim season with important lessons on how to stay water ... Polar Bear Who Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3
... 2007) Rutgers College of Nursing faculty member Rachel ... the Rutgers-Newark Provosts Award for Community Engagement in Research. ... based in whole or in part on data from ... Rutgers-Newark provost, established the Provosts Awards for Community Engagement ...
... Nov. 26 Flagship Global Health,Inc. (OTC Bulletin Board: FGHH) ... 29, 2007. Mr. Fred Nazem, Chairman, and Mr. John Flood,III, ... and will be,giving a detailed update on the progress that ... what is anticipated in the near future., The dial ...
... allows medical professionals to instantly ... access and manipulate patient ... global leader in,software-driven systems for targeted, less-invasive medical treatments,today ... the,Annual Meeting of the Radiological Society of North America ...
... Capital, Inc. (Nasdaq: ACAP ) today announced that ... its Board of,Directors on May 22, 2007 under its ... as of September 30, 2007.,The Company has commenced its ... of Directors on August 16, 2007., "I am ...
... Image Quality for a Wide ... 26 MCCORMICK PLACE, HALL A, BOOTH #3382,-- Alara ... products, today announced it is showcasing the CRystalView T-Series,desktop ... has received US Food,and Drug Administration clearance to market ...
... activities help students identify their unique qualities ... while appreciating those of others, ... Can, in,partnership with Scholastic, announced today the distribution of free,teaching ... discover their own special abilities and qualities and appreciate unique,qualities ...
Cached Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 3Health News:American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program 2Health News:American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program 3Health News:Alara Receives FDA Clearance to Market CRystalView T-Series CR system 2Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 2Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 3
... Our soft, flexible whistle tip ... sterile kit that includes: suction catheter, ... gloves. Components are packed in order ... catheter inside a labeled tissue envelope. ...
... Maxi-Flo® suction catheters ... or straight. , ... catheter kits are latex-free., ... feature a catheter tip ...
... a single lumen or dual lumen catheter. ... ,Trac-Wedge™ device, and patient label with ... label. Dual swivel elbow kits do not ... systems are latex-free. , ...
Touch-Trol Pediatric Suction Catheter Mini-Tray...
Medicine Products: